ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Serglycin is Involved in TGF-β induced epithelial-mesenchymal transition and is highly expressed by immune cells in breast cancer tissue

Permanent lenke
https://hdl.handle.net/10037/26465
DOI
https://doi.org/10.3389/fonc.2022.868868
Thumbnail
Åpne
article.pdf (8.222Mb)
Publisert versjon (PDF)
Dato
2022-04-14
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Tellez Gabriel, Marta; Tekpli, Xavier; Reine, Trine M.; Hegge, Beate; Nielsen, Stephanie Rose; Chen, Meng; Moi, Line; Normann, Lisa Svartdal; Rasmussen Busund, Lill-Tove; Calin, George A.; Mælandsmo, Gunhild Mari; Perander, Maria; Theocharis, Achilleas D.; Kolset, Svein Olav; Knutsen, Erik
Sammendrag
Serglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, and other bioactive molecules. In recent years, it has been demonstrated that serglycin is also expressed by several other cell types, such as endothelial cells, muscle cells, and multiple types of cancer cells. Here, we show that serglycin expression is upregulated in transforming growth factor beta (TGF-b) induced epithelial-mesenchymal transition (EMT). Functional studies provide evidence that serglycin plays an important role in the regulation of the transition between the epithelial and mesenchymal phenotypes, and it is a significant EMT marker gene. We further find that serglycin is more expressed by breast cancer cell lines with a mesenchymal phenotype as well as the basal-like subtype of breast cancers. By examining immune staining and single cell sequencing data of breast cancer tissue, we show that serglycin is highly expressed by infiltrating immune cells in breast tumor tissue.
Forlag
Frontiers Media
Sitering
Tellez Gabriel, Tekpli, Reine, Hegge, Nielsen, Chen, Moi, Normann, Rasmussen Busund, Calin, Mælandsmo, Perander, Theocharis, Kolset, Knutsen. Serglycin is Involved in TGF-β induced epithelial-mesenchymal transition and is highly expressed by immune cells in breast cancer tissue. Frontiers in Oncology. 2022;12:868868:1-13
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (medisinsk biologi) [1103]
Copyright 2022 The Author(s)

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring